Mediation role of body fat distribution (FD) on the relationship between CAV1 rs3807992 polymorphism and metabolic syndrome in overweight and obese women

Abstract

Background Metabolic syndrome (MetS) is associated with an increased risk of morbidity and mortality in almost all chronic diseases. The most frequent methods for the calculation of a continuous MetS (cMetS) score have used the standardized residuals in linear regression (z-score). Recently, emerging data suggest that one of the main genetic targets is the CAV1, which plays a crucial role in regulating body fat distribution. This study is designed to investigate the relationship between CAV1 rs3807992 genotypes and cMetS, and to determine whether body fat distribution plays a mediating role in this regard. Methods The current cross-sectional study was conducted on 386 overweight and obese females. The CAV1 rs3807992 and body composition were measured by the PCR–RFLP method and bioelectrical impedance analysis, respectively. Serum profile of HDL-C, TGs, FPG, and Insulin were measured by standard protocols. Results GG allele carriers had significantly lowered Z-MAP (p = 0.02), total cMetS (p = 0.03) and higher Z-HDL (p = 0.001) compared with (A) allele carriers. There was a significant specific indirect effect (standardized coefficient = 0.19; 95% CI 0.01–0.4) of Visceral fat level (VFL). Although, total body fat was significantly associated with CAV1 rs3807992 and cMetS, the specific indirect effect was not significant (standardized coefficient = 0.21; 95% CI − 0.006, 0.44). VFL contributed to significant indirect effects of 35% on the relationship between CAV1 and cMetS. Conclusion Higher visceral adipose tissue may affect the relationship between CAV1 and cMetS. Although CAV1 rs3807992 is linked to VFL in our study, the influence of this polymorphism on MetS is not via total fat.

Caveolin-1 rs1997623 Single Nucleotide Polymorphism Creates a New Binding Site for the Early B-Cell Factor 1 That Instigates Adipose Tissue CAV1 Protein Overexpression

“…Little is known about CAV1 regulation in adipocytes; single nucleotide polymorphisms (SNPs) in the CAV1 gene have been associated with metabolic syndrome (MetS), which is a major risk factor for diabetes and coronary artery disease. Several CAV1 SNPs were found to be associated with MetS, including rs926198 in Caucasians and Hispanics [ 11 ], rs3807989 in Han Chinese [ 12 ], rs11773845 in Latin Americans [ 13 ], rs3807992 in Persians [ 14 ], and rs1997623 in Kuwaiti children, as shown in our previous study [ 15 ], and as found in another adult population [ 16 ]. Although central obesity is a landmark trait for the diagnosis of MetS, the full spectrum of traits relating to MetS includes various other metabolic factors related to hypertension, diabetes, and dyslipidemia.…”

Bioinformatics and Next-Generation Data Analysis for Identification of Genes and Molecular Pathways Involved in Subjects with Diabetes and Obesity

“…VIM (vimentin) binds to insulin-responsive aminopeptidas, a major cargo protein of glucose transporter type 4, and decreases the glucose tolerance [ 182 ]. IFI16 [ 193 ], ERBB2 [ 194 ], VIM (vimentin) [ 182 , 195 ] and CAV1 [ 160 , 196 , 197 , 198 , 199 ] are crucial factors for advancement of obesity. IFI16 showed adipogenesis, an enhanced inflammatory state and damaged insulin-stimulated glucose uptake in adipose tissue [ 193 ].…”

Interaction of Caveolin-1 gene polymorphism with processed meats on anthropometric measurements and body composition in obese and overweight women: A cross-sectional study

“…It has been suggested that some possible functional roles for CAV-1 may be inherited. CAV-1 has also been shown to have a key regulatory function in fat distribution and genetic lipodystrophy in humans (40).A cross-sectional study has reported that processed meat consumption (6.8 g/d) compared to white meat/poultry is more likely to be associated with central obesity (15). In a study, Halkjaer et al showed that a diet rich in processed meat predicts high level of WC among 89 432 men and women from ve countries participating in European Prospective Investigation into Cancer and Nutrition (EPIC) (41).…”